Faruqi & Faruqi, LLP is actively investigating potential claims on behalf of investors in Jasper Therapeutics, Inc. Following a significant decline in the company’s stock price, the firm urges those who purchased shares between November 30, 2023, and July 3, 2025, to consider their legal options. Interested investors are encouraged to contact James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
On July 7, 2025, Jasper disclosed troubling data from its BEACON Study, which led to a dramatic drop in its stock price. The company revealed that results from specific dosage cohorts were compromised due to issues with one drug product lot. This announcement prompted the stock to plummet by $3.73 per share, equating to a 55.1% decline, closing at $3.04 per share.
Legal Actions and Investor Rights
The firm reminds investors that there is a critical deadline of November 18, 2025 for those wishing to serve as lead plaintiffs in a federal securities class action against Jasper. The lead plaintiff will represent the interests of all investors within the class, providing oversight for the litigation process. Investors have the option to either pursue this role or remain as absent class members, with their ability to recover losses unaffected by their choice.
The allegations against Jasper include claims that the company and its executives violated federal securities laws through misleading statements and failure to disclose critical operational issues. The complaint highlights that Jasper lacked the necessary controls to ensure compliance with current Good Manufacturing Practices (cGMP) among its third-party manufacturers, which jeopardized the integrity of its clinical trials.
Furthermore, the lawsuit alleges that these shortcomings increased the likelihood of adverse outcomes in ongoing studies, thus overstating the company’s financial and operational prospects, particularly concerning its lead product, briquilimab.
Next Steps for Investors
Following the alarming announcement, Jasper announced it would halt the ETESIAN Study and pause development of briquilimab in asthma, alongside other cost-cutting measures. The firm also indicated that previous assertions regarding its financial health were overstated, prompting concerns among investors.
Faruqi & Faruqi, LLP, a national securities law firm with a history of recovering substantial amounts for investors, invites anyone with information related to Jasper’s practices, including whistleblowers and former employees, to reach out. The firm emphasizes that communications will remain confidential.
For further details regarding the ongoing investigation or to learn more about the class action against Jasper Therapeutics, individuals can visit [Faruqi & Faruqi’s website](http://www.faruqilaw.com/JSPR) or contact Josh Wilson directly.
As the situation develops, investors are encouraged to remain informed and consider their legal rights in light of these significant events.
